<DOC>
	<DOCNO>NCT00301535</DOCNO>
	<brief_summary>The purpose study determine Hemopure® enhance tissue preservation Cardiopulmonary Bypass surgery .</brief_summary>
	<brief_title>A Study Hemopure® Enhance Tissue Preservation During Cardiopulmonary Bypass Surgery</brief_title>
	<detailed_description>The primary objective determine safety feasibility administer Hemopure® ( HBOC-201 ) reduce myocardial necrosis , measure CK-MB enzyme elevation , enhance tissue preservation cardiopulmonary bypass .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>HBOC 201</mesh_term>
	<criteria>Subject age 18 80 . Subject acceptable candidate CABG . Subject schedule CABG ( without plan valvular repair replacement ) cardiopulmonary bypass . Subject sign inform consent Subject treat physician agree subject comply study procedure followup visit time subject screening . Preoperative myocardial infarction , define CKMB level &gt; 2 time upper limit normal 24 hour prior CABG surgery . Renal failure define serum creatinine great 220 µmol/L Subject ejection fraction ≤ 30 % ( measure Echocardiography within 30 day study enrollment ) . Active infection . History prior stroke within last six month history prior stroke residual neurological deficit . Transient Ischemic attack within last 6 month . Subject history coagulopathy . Subject pregnant currently breastfeed . History allergy beef product . Preoperative cardiogenic shock define cardiac index ≤ 1.8.L/min/m2 despite use vasopressor . Underlying medical condition would limit subject 's life expectancy le 12 month . Severe pulmonary disease [ base upon clinical diagnosis pulmonary function test ( FEV &lt; 1 liter ) , available ] may interfere wean subject ventilator . History acute central nervous disorder ( e.g. , seizure traumatic injury ) . Severe hypertension ( ≥ 160/90 mm Hg ) medically control despite treatment two antihypertensive therapy . Severe liver dysfunction define total bilirubin ≥ 51 µmol/L 2 time site normal limit AST ALT activity . Subject systemic mastocytosis . Subject condition predisposes subject systemic mast cell degranulation hypersensitivity reaction history severe allergic reaction drug environmental allergen . Subject participate another investigational drug , biologic device study within 30 day prior study enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Coronary Artery Bypass Graft</keyword>
	<keyword>memory loss cardiac surgery</keyword>
	<keyword>side effect bypass</keyword>
</DOC>